Penciclovir_NP Susceptibilities_NP of_IN Herpes_NP Simplex_NP Virus_NP Isolates_NP from_IN Patients_NPS Using_VBG Penciclovir_NP Cream_NP for_IN Treatment_NP of_IN Recurrent_NP Herpes_NP Labialis_NP The_DT antiherpesvirus_NN agent_NN penciclovir_NN (_( PCV_NP )_) shares_VBZ an_DT identical_JJ activation_NN pathway_NN and_CC a_DT similar_JJ mode_NN of_IN action_NN with_IN acyclovir_NN (_( ACV_NP )_) ._SENT However_RB ,_, since_IN PCV_NP represents_VBZ a_DT relatively_RB recent_JJ treatment_NN option_NN ,_, the_DT clinical_JJ resistance_NN profile_NN to_TO PCV_NP is_VBZ less_RBR well_RB known_VBN ._SENT A_DT susceptibility_NN program_NN was_VBD established_VBN to_TO assess_VB the_DT resistance_NN profile_NN for_IN serial_JJ herpes_NN simplex_JJ virus_NN isolates_NNS from_IN immunocompetent_JJ patients_NNS with_IN recurrent_JJ herpes_NN labialis_NNS obtained_VBN throughout_IN a_DT 4-day_JJ period_NN of_IN treatment_NN with_IN topical_JJ PCV_NP (_( 1_CD %_NN cream_NN )_) or_CC a_DT placebo_NN ._SENT Two_CD isolates_NNS (_( 2_CD of_IN 1,035_CD [_SYM 0.19_CD %_NN ]_SYM )_) ,_, representing_VBG 0.34_CD %_NN of_IN the_DT patients_NNS (_( 2_CD of_IN 585_CD )_) ,_, were_VBD confirmed_VBN to_TO be_VB PCV-resistant_JJ (_( Pcvr_NP )_) herpes_NN simplex_JJ virus_NN type_NN 1_CD by_IN a_DT plaque_NN reduction_NN assay_NN in_IN MRC-5_NP cells_NNS ._SENT These_DT two_CD viruses_NNS were_VBD highly_RB resistant_JJ to_TO PCV_NP (_( 50_CD %_NN inhibitory_JJ concentrations_NNS [_SYM IC50s_NP ]_SYM ,_, >55_JJ mug/ml_NN )_) and_CC were_VBD isolated_VBN less_JJR than_IN 17_CD h_NN after_IN the_DT start_NN of_IN patient-initiated_JJ treatment_NN ._SENT However_RB ,_, subsequent_JJ isolates_NNS on_IN days_NNS 2_CD and_CC 3_CD from_IN these_DT patients_NNS were_VBD completely_RB susceptible_JJ to_TO PCV_NP (_( IC50s_NP ,_, <2.0_NN mug/ml_NN )_) ._SENT Thus_RB ,_, it_PP is_VBZ not_RB clear_JJ whether_IN the_DT resistance_NN to_TO PCV_NP for_IN these_DT two_CD early-treatment_NN isolates_NNS was_VBD directly_RB associated_VBN with_IN the_DT 17_CD h_NN of_IN PCV_NP treatment_NN ;_: several_JJ possible_JJ explanations_NNS are_VBP discussed_VBN ._SENT In_IN an_DT analysis_NN of_IN the_DT distribution_NN of_IN IC50_JJ differences_NNS between_IN the_DT first_JJ and_CC last_JJ isolates_NNS ,_, there_EX were_VBD three_CD patients_NNS with_IN minor_JJ IC50_NP increases_NNS in_IN the_DT PCV-treated_JJ population_NN and_CC one_CD in_IN the_DT placebo-treated_JJ group_NN ,_, although_IN statistically_RB ,_, only_RB the_DT latter_NN was_VBD an_DT outlier_NN ._SENT No_DT patients_NNS were_VBD found_VBN to_TO have_VB Pcvr_NP virus_NN at_IN the_DT end_NN of_IN acute_JJ treatment_NN ,_, regardless_RB of_IN treatment_NN group_NN ._SENT Overall_RB ,_, the_DT prevalence_NN of_IN Pcvr_NP was_VBD found_VBN to_TO be_VB similar_JJ to_TO the_DT 0.3_CD %_NN Acvr_NP reported_VBD for_IN immunocompetent_JJ ,_, untreated_JJ populations_NNS ._SENT The_DT use_NN of_IN acyclovir_NN (_( ACV_NP )_) and_CC penciclovir_NP (_( PCV_NP )_) in_IN treating_VBG herpesvirus_NN infections_NNS has_VBZ increased_VBN significantly_RB since_IN the_DT introduction_NN of_IN ACV_NP 2_CD decades_NNS ago_RB ._SENT These_DT nucleoside_NN analogues_NNS of_IN guanine_NN are_VBP preferentially_RB phosphorylated_JJ to_TO monophosphate_NN by_IN the_DT viral_JJ thymidine_NN kinase_NN (_( TK_NP )_) and_CC subsequently_RB converted_VBN to_TO ACV_NP triphosphate_NN by_IN cellular_JJ enzymes_NNS ._SENT The_DT activated_VBN triphosphate_NN inhibits_VBZ viral_JJ DNA_NN polymerase_NN activity_NN and_CC prevents_VBZ viral_JJ DNA_NN elongation_NN ._SENT Herpes_NN simplex_NN virus_NN (_( HSV_NP )_) resistance_NN to_TO these_DT agents_NNS typically_RB develops_VBZ by_IN mutations_NNS in_IN the_DT TK_NP gene_NN ,_, although_IN mutations_NNS within_IN the_DT viral_JJ DNA_NN polymerase_NN can_MD also_RB confer_VB ACV_NP resistance_NN (_( -_: ,_, ,_, )_) ._SENT ACV-resistant_NP (_( Acvr_NP )_) HSV_NP variants_NNS have_VBP been_VBN readily_RB isolated_VBN in_IN culture_NN after_IN sequential_JJ passages_NNS in_IN the_DT presence_NN of_IN increasing_VBG concentrations_NNS of_IN ACV_NP (_( reviewed_VBN in_IN reference_NN )_) ._SENT However_RB ,_, several_JJ studies_NNS suggest_VBP that_IN clinical_JJ use_NN of_IN ACV_NP has_VBZ not_RB been_VBN associated_VBN with_IN an_DT increased_VBN emergence_NN of_IN drug-resistant_JJ virus_NN ._SENT Sensitivity_NN monitoring_NN surveys_NNS have_VBP revealed_VBN that_IN since_IN the_DT introduction_NN of_IN ACV_NP ,_, the_DT prevalence_NN of_IN resistance_NN in_IN the_DT general_JJ population_NN has_VBZ remained_VBN unchanged_JJ ,_, and_CC little_RB if_IN any_DT impact_NN on_IN the_DT prevalence_NN of_IN resistant_JJ virus_NN in_IN the_DT immunocompetent_JJ population_NN has_VBZ been_VBN shown_VBN ._SENT Clinically_RB significant_JJ resistance_NN to_TO ACV_NP has_VBZ been_VBN limited_VBN almost_RB exclusively_RB to_TO the_DT immunocompromised_JJ population_NN ,_, in_IN which_WDT approximately_RB 4_CD to_TO 10_CD %_NN of_IN patients_NNS develop_VBP resistance_NN during_IN antiviral_JJ treatment_NN ._SENT To_TO discern_VB the_DT prevalence_NN of_IN PCV_NP resistance_NN in_IN the_DT immunocompetent_JJ population_NN ,_, susceptibility_NN assays_NNS were_VBD performed_VBN on_IN virus_NN isolates_NNS from_IN patients_NNS participating_VBG in_IN two_CD placebo-controlled_VBN trials_NNS for_IN evaluation_NN of_IN the_DT efficacy_NN of_IN topical_JJ PCV_NP for_IN recurrent_JJ herpes_NN labialis_NNS (_( ;_: unpublished_JJ data_NNS )_) ._SENT Isolate_NN sampling_NN and_CC resistance_NN breakpoint_NN ._SENT |_SYM Topical_NP PCV_NP cream_NN (_( 1_CD %_NN )_) was_VBD evaluated_VBN as_IN a_DT treatment_NN for_IN recurrent_JJ herpes_NN labialis_NNS in_IN two_CD phase_NN III_CD studies_NNS conducted_VBD according_VBG to_TO the_DT same_JJ protocol_NN ._SENT Patients_NNS were_VBD instructed_VBN to_TO apply_VB PCV_NP or_CC placebo_NN cream_NN nine_CD times_NNS per_IN day_NN for_IN 4_CD days_NNS within_IN 1_CD h_NN of_IN the_DT first_JJ sign_NN or_CC symptom_NN of_IN a_DT recurrence_NN ._SENT Although_IN treatment_NN was_VBD initiated_VBN by_IN the_DT patient_NN ,_, the_DT patients_NNS visited_VBD the_DT study_NN center_NN daily_JJ for_IN evaluation_NN and_CC virus_NN isolation_NN ._SENT Additionally_RB ,_, each_DT patient_NN kept_VBD a_DT daily_JJ record_NN of_IN treatment_NN time_NN and_CC compliance_NN ._SENT To_TO determine_VB the_DT pattern_NN of_IN virus_NN susceptibility_NN to_TO PCV_NP ,_, antiviral_JJ assays_NNS were_VBD performed_VBN on_IN the_DT first_JJ and_CC last_JJ virus_NN isolates_NNS obtained_VBN from_IN the_DT patients_NNS ._SENT In_IN some_DT instances_NNS ,_, additional_JJ isolates_NNS obtained_VBN at_IN intervals_NNS between_IN the_DT samplings_NNS for_IN the_DT first_JJ and_CC last_JJ isolates_NNS were_VBD obtained_VBN and_CC also_RB tested_VBN ._SENT The_DT first_JJ isolate_NN was_VBD defined_VBN as_IN the_DT virus_NN isolated_VBN within_IN 24_CD h_NN of_IN the_DT start_NN of_IN topical_JJ PCV_NP treatment_NN ._SENT The_DT last_JJ isolate_NN was_VBD defined_VBN as_IN the_DT final_JJ virus-positive_JJ culture_NN obtained_VBD ._SENT In_IN practice_NN these_DT were_VBD obtained_VBN during_IN the_DT treatment_NN period_NN or_CC after_IN cessation_NN of_IN treatment_NN ._SENT Virus_NN isolates_NNS were_VBD taken_VBN during_IN the_DT vesicle_NN to_TO soft-crust_NN stage_NN ._SENT The_DT mean_JJ interval_NN between_IN first_JJ and_CC last_JJ isolates_NNS was_VBD 1.8_CD days_NNS for_IN the_DT PCV_NP group_NN and_CC 1.9_CD days_NNS for_IN the_DT placebo_NN group_NN ._SENT In_IN order_NN to_TO determine_VB the_DT pattern_NN of_IN virus_NN susceptibility_NN ,_, antiviral_JJ assays_NNS were_VBD performed_VBN on_IN a_DT random_JJ ,_, blinded_VBD sample_NN of_IN isolates_NNS from_IN each_DT study_NN ._SENT An_DT in_IN vitro_NN breakpoint_NN for_IN defining_VBG ACV_NP resistance_NN has_VBZ been_VBN set_VBN at_IN 2.0_CD mug/ml_NN ,_, since_IN 50_CD %_NN inhibitory_JJ concentrations_NNS (_( IC50s_NP )_) for_IN isolates_NNS from_IN individuals_NNS failing_VBG to_TO respond_VB to_TO drug_NN therapy_NN were_VBD generally_RB above_IN this_DT level_NN ._SENT Breakpoints_NNS are_VBP typically_RB established_VBN through_IN a_DT consensus_NN of_IN researchers_NNS in_IN the_DT field_NN based_VBN on_IN the_DT correlation_NN between_IN clinical_JJ treatment_NN failure_NN and_CC in_IN vitro_NP IC50s_NP ._SENT Because_IN there_EX is_VBZ no_RB recognized_VBN in_IN vitro_NN breakpoint_NN for_IN defining_VBG resistance_NN to_TO PCV_NP ,_, provisional_JJ guidelines_NNS were_VBD set_VBN for_IN defining_VBG resistance_NN based_VBN on_IN the_DT susceptibility_NN of_IN the_DT sensitive_JJ control_NN virus_NN strain_NN to_TO PCV_NP ,_, which_WDT was_VBD determined_VBN in_IN each_DT assay_NN ._SENT This_DT takes_VBZ into_IN account_NN the_DT known_VBN variation_NN in_IN IC50s_NP between_IN laboratories_NNS ._SENT Resistance_NN was_VBD defined_VBN as_IN an_DT IC50_NN of_IN >=2.0_JJ mug/ml_NN or_CC an_DT IC50_NP >10-fold_NN higher_JJR than_IN the_DT IC50_NN for_IN the_DT wild-type_JJ sensitive_JJ control_NN virus_NN within_IN that_DT particular_JJ assay_NN ._SENT Virological_JJ work_NN was_VBD performed_VBN at_IN two_CD College_NP of_IN American_NP Pathology-approved_NP centers_NNS (_( the_DT clinical_JJ virology_NN laboratories_NNS of_IN the_DT Children_NP 's_POS Hospital_NP of_IN Philadelphia_NP and_CC the_DT University_NP of_IN San_NP Francisco_NP General_NP Hospital_NP )_) ,_, and_CC each_DT center_NN used_VBD wild-type_JJ HSV_NP type_NN 1_CD (_( HSV-1_NP )_) as_IN a_DT standard_JJ virus_NN for_IN susceptibility_NN assays_NNS (_( either_CC strain_NN SC16_NN or_CC strain_NN F_NN ,_, depending_VBG on_IN the_DT center_NN )_) ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Analysis_NN of_IN covariance_NN was_VBD used_VBN to_TO determine_VB whether_IN HSV_NP isolates_VBZ from_IN PCV-treated_JJ patients_NNS and_CC placebo-treated_JJ patients_NNS had_VBD different_JJ last_JJ IC50s_NNS after_IN comparison_NN with_IN their_PP$ respective_JJ first_JJ IC50s_NNS ._SENT The_DT analysis_NN was_VBD performed_VBN using_VBG natural_JJ logarithms_NNS of_IN the_DT IC50s_NP ,_, which_WDT provides_VBZ statistical_JJ stringency_NN ._SENT It_PP was_VBD assumed_VBN that_IN within_IN each_DT treatment_NN group_NN ,_, the_DT average_JJ difference_NN between_IN last_JJ and_CC first_JJ isolates_NNS was_VBD zero_CD ,_, and_CC significant_JJ deviation_NN from_IN zero_CD would_MD indicate_VB a_DT trend_NN ._SENT Statistically_RB significant_JJ differences_NNS in_IN the_DT change_NN from_IN the_DT first_JJ to_TO the_DT last_JJ IC50_NN between_IN PCV-treated_JJ and_CC placebo-treated_JJ groups_NNS would_MD be_VB indicated_VBN by_IN a_DT P_NN value_NN of_IN less_JJR than_IN 0.05_CD ._SENT Similarly_RB ,_, it_PP was_VBD assumed_VBN that_IN between_IN the_DT two_CD treatment_NN groups_NNS ,_, the_DT average_JJ difference_NN between_IN first_JJ isolates_NNS was_VBD zero_CD and_CC the_DT average_JJ difference_NN between_IN last_JJ isolates_NNS was_VBD zero_CD ;_: a_DT P_NN value_NN below_IN 0.05_CD would_MD suggest_VB a_DT trend_NN ._SENT Virus_NN culture_NN ._SENT |_SYM Lesions_NP were_VBD swabbed_VBN daily_RB throughout_IN the_DT course_NN of_IN the_DT recurrence_NN ,_, during_IN treatment_NN ,_, and_CC often_RB after_IN treatment_NN had_VBD ceased_VBN ,_, to_TO maximize_VB the_DT chance_NN of_IN identifying_VBG Pcvr_NP isolates_NNS ._SENT Briefly_RB ,_, Dacron_NP swabs_NNS moistened_VBN with_IN Viral-Chlamydial_NP transport_NN medium_NN (_( Carr-Scarborough_NP Microbiologicals_NP ,_, Decatur_NP ,_, Ga._NP )_) were_VBD used_VBN to_TO swab_VB the_DT lesions_NNS ._SENT Swabs_NNS were_VBD placed_VBN in_IN transport_NN medium_NN and_CC either_RB processed_VBN immediately_RB for_IN virus_NN isolation_NN or_CC stored_VBN at_IN 4C_JJ for_IN no_DT more_JJR than_IN 48_CD h._JJ Human_JJ diploid_JJ fibroblast_NN cells_NNS in_IN shell_JJ vials_NNS were_VBD inoculated_VBN with_IN the_DT transport_NN medium_NN and_CC incubated_VBD overnight_RB at_IN 37C_JJ ._SENT Resistant_JJ virus_NN isolates_NNS were_VBD typed_VBN by_IN staining_VBG of_IN viral_JJ antigens_NNS with_IN type-specific_JJ monoclonal_NN antibodies_NNS (_( Dako_NP )_) and_CC were_VBD confirmed_VBN to_TO be_VB HSV-1_JJ ._SENT All_DT other_JJ virus_NN isolates_NNS were_VBD presumed_VBN to_TO be_VB HSV-1_JJ ,_, although_IN not_RB directly_RB typed_VBN ._SENT Plaque_NN reduction_NN assay_NN ._SENT |_SYM Testing_NP of_IN susceptibility_NN to_TO PCV_NP was_VBD performed_VBN by_IN the_DT plaque_NN reduction_NN assay_NN method_NN in_IN human_JJ diploid_JJ fibroblast_NN cells_NNS (_( MRC-5_NP )_) between_IN passages_NNS 12_CD and_CC 20_CD ._SENT Briefly_RB ,_, cells_NNS were_VBD seeded_VBN into_IN 12-well_NP microtiter_NN plates_NNS at_IN approximately_RB 3_CD x_SYM 105/well_NP in_IN 1.0_CD ml_NN of_IN Eagle_NP 's_POS minimum_JJ essential_JJ medium_NN containing_VBG 10_CD %_NN fetal_JJ calf_NN serum_NN or_CC into_IN 24-well_JJ plates_NNS with_IN approximately_RB one-half_JJ the_DT number_NN of_IN cells_NNS ._SENT Cells_NNS were_VBD inoculated_VBN with_IN 10-fold_JJ dilutions_NNS (_( 102_CD to_TO 104_CD )_) of_IN the_DT viral_JJ isolate_NN for_IN 1_CD h_NN at_IN 37C_JJ in_IN a_DT final_JJ volume_NN of_IN 0.5_CD ml_NN of_IN Hanks_NP buffered_VBD salt_NN solution_NN ._SENT Testing_NN was_VBD performed_VBN in_IN triplicate_NN in_IN MRC-5_NP cells_NNS by_IN using_VBG a_DT series_NN of_IN PCV_NP concentrations_NNS over_IN 10_CD or_CC 11_CD serial_JJ dilutions_NNS to_TO provide_VB at_IN least_JJS two_CD data_NNS points_NNS on_IN either_DT side_NN of_IN the_DT IC50_NP ._SENT After_IN virus_NN adsorption_NN ,_, the_DT drug_NN ,_, 2x_NP Eagle_NP 's_POS minimum_JJ essential_JJ medium_NN ,_, and_CC 0.8_CD %_NN (_( wt/vol_NN )_) SeaPlaque_NP agarose_NP (_( FMC_NP Bioproducts_NP )_) were_VBD mixed_VBN ,_, and_CC 3.0-ml_JJ volumes_NNS were_VBD added_VBN to_TO each_DT well_NN of_IN a_DT 12-well_NP plate_NN ._SENT After_IN 3_CD days_NNS at_IN 37C_JJ ,_, plates_NNS were_VBD fixed_VBN with_IN 1.0_CD ml_NN of_IN 10_CD %_NN formaldehyde_NN solution_NN for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT Cell_NN monolayers_NNS were_VBD stained_VBN with_IN crystal_NN violet_NN after_IN removal_NN of_IN the_DT agarose_JJ plugs_NNS ._SENT Plaque_NN numbers_NNS were_VBD counted_VBN ,_, and_CC IC50s_NP were_VBD calculated_VBN ._SENT Plaque_NN reduction_NN assays_NNS on_IN the_DT resistant_JJ isolates_NNS were_VBD performed_VBN in_IN D21_JJ cells_NNS ,_, a_DT line_NN derived_VBN from_IN BUHK-TK_NP cells_NNS which_WDT constitutively_RB expresses_VBZ an_DT HSV_NP TK_NP gene_NN ,_, as_RB described_VBN in_IN reference_NN ._SENT These_DT cells_NNS were_VBD a_DT kind_NN gift_NN from_IN H._NP Field_NP (_( University_NP of_IN Cambridge_NP ,_, Cambridge_NP ,_, United_NP Kingdom_NP )_) ._SENT These_DT transformed_VBN cells_NNS were_VBD maintained_VBN in_IN modified_JJ Eagle_NP 's_POS medium_NN with_IN 10_CD %_NN calf_NN serum_NN and_CC HAT_NN supplement_NN (_( hypoxanthine_NN ,_, aminopterin_NN ,_, and_CC thymidine_NN )_) ._SENT For_IN resistant_JJ samples_NNS ,_, susceptibilities_NNS to_TO ACV_NP and_CC foscarnet_NP were_VBD also_RB determined_VBN by_IN the_DT plaque_NN reduction_NN assay_NN ,_, with_IN compounds_NNS obtained_VBN from_IN Sigma_NP Chemical_NP Co._NP (_( St._NP Louis_NP ,_, Mo._NP )_) ._SENT TK_NP assay_NN ._SENT |_SYM Viral_NP TK_NP activity_NN was_VBD determined_VBN by_IN a_DT modification_NN of_IN the_DT method_NN described_VBN by_IN Coen_NP and_CC Schaffer_NP ._SENT Human_NP 143_CD TK-negative_JJ cells_NNS seeded_VBN in_IN duplicate_JJ 100-mm_NP dishes_NNS were_VBD infected_VBN at_IN 5_CD PFU/cell_NN with_IN the_DT HSV_NP preparation_NN in_IN a_DT Beckman_NP G6-CR_NP tabletop_NN centrifuge_NN ,_, in_IN 4.0_CD ml_NN of_IN serum-free_JJ medium_NN ._SENT Parallel_JJ cell_NN monolayers_NNS were_VBD mock_JJ infected_JJ ._SENT One_CD hour_NN postinfection_NN ,_, monolayers_NNS were_VBD rinsed_VBN with_IN phosphate-buffered_JJ saline_NN ,_, and_CC fresh_JJ medium_NN was_VBD added_VBN for_IN 8_CD h._JJ Infected_JJ cells_NNS were_VBD then_RB rinsed_VBN with_IN phosphate-buffered_JJ saline_NN ,_, scraped_VBD ,_, and_CC centrifuged_VBD for_IN 10_CD min_NN at_IN 1,000_CD rpm_NN (_( 4C_JJ )_) and_CC cell_NN pellets_NNS were_VBD frozen_VBN at_IN -80C_NN ._SENT Thawed_VBN pellets_NNS were_VBD resuspended_VBN in_IN 300_CD mul_NN of_IN 10_CD mM_NP sodium_NN phosphate_NN buffer_NN (_( pH_NN 6.0)-5_JJ mM_NP 2-mercaptoethanol-10_JJ %_NN glycerol-50_NN muM_NN thymidine_NN ._SENT Extracts_VBZ were_VBD sonicated_VBN on_IN ice_NN and_CC centrifuged_VBD to_TO remove_VB cellular_JJ debris_NN ._SENT This_DT extract_NN (_( 9_CD mul_NN )_) was_VBD added_VBN to_TO a_DT mixture_NN to_TO yield_VB final_JJ concentrations_NNS of_IN 100_CD mM_NP sodium_NN phosphate_NN (_( pH_NN 6.0_CD )_) ,_, 10_CD mM_NP ATP_NP ,_, 10_CD mM_NP magnesium_NN acetate_NN ,_, 6_CD muCi_NNS of_IN [_SYM 3H]thymidine_JJ (_( 11_CD Ci/mmol_NP ;_: NEN_NP Research_NP Products_NP )_) ,_, 50_CD muM_NN TTP_NP ,_, 25_CD mM_NP NaI_NP ,_, 0.67_CD mM_NP dithiothreitol_NN ,_, and_CC 10_CD mug_NN of_IN bovine_JJ serum_NN albumin/ml_NN in_IN a_DT final_JJ volume_NN of_IN 30_CD mul_NN ._SENT Reaction_NN mixtures_NNS were_VBD incubated_VBN at_IN 30C_JJ ._SENT At_IN various_JJ times_NNS ranging_VBG from_IN 0_CD to_TO 180_CD min_NN after_IN addition_NN of_IN the_DT cell_NN extract_NN ,_, 5-mul_NP aliquots_NNS were_VBD removed_VBN ,_, added_VBD to_TO 20_CD mul_NN of_IN 1_CD mM_NP thymidine_NN ,_, and_CC boiled_VBD for_IN 2_CD min_NN ._SENT Samples_NNS were_VBD then_RB spotted_VBN onto_IN Whatman_NP DE81_NP circle_NN filters_NNS ._SENT After_IN drying_VBG ,_, the_DT filters_NNS were_VBD washed_VBN three_CD times_NNS with_IN 4_CD mM_NP ammonium_NN formate_NN and_CC 10_CD muM_NN thymidine_NN ,_, once_RB with_IN distilled_JJ water_NN ,_, and_CC twice_RB with_IN ethanol_NN ._SENT Dry_JJ filters_NNS were_VBD placed_VBN in_IN scintillation_NN vials_NNS with_IN Betafluor_NP and_CC counted_VBN ._SENT Values_NNS from_IN duplicate_JJ samples_NNS were_VBD averaged_VBN ._SENT Radioactivity_NN from_IN the_DT mock-infected_JJ control_NN processed_VBN in_IN parallel_NN was_VBD used_VBN to_TO subtract_VB background_NN ._SENT Data_NP points_NNS from_IN the_DT linear_JJ range_NN of_IN thymidine_NN phosphorylation_NN were_VBD used_VBN ._SENT TK_NP activity_NN for_IN HSV-1_NP SC16_NP was_VBD set_VBN at_IN 100_CD %_NN ._SENT The_DT limit_NN of_IN detection_NN was_VBD estimated_VBN to_TO be_VB 0.3_CD %_NN ,_, in_IN agreement_NN with_IN a_DT previous_JJ report_NN ._SENT PCV_NP susceptibilities_NNS of_IN paired_VBN HSV_NP isolates_VBZ ._SENT |_SYM Sensitivity_NN testing_NN was_VBD performed_VBN on_IN a_DT total_NN of_IN 1,035_CD isolates_NNS from_IN 585_CD patients_NNS ,_, of_IN which_WDT 864_CD (_( 83_CD %_NN )_) represented_VBD paired_VBN isolates_NNS (_( first_JJ and_CC last_JJ isolate_NN obtained_VBN from_IN each_DT patient_NN )_) ._SENT Of_IN the_DT paired_VBN isolates_NNS ,_, 358_CD were_VBD from_IN PCV-treated_JJ patients_NNS and_CC 506_CD were_VBD from_IN the_DT placebo-treated_JJ group_NN ._SENT The_DT IC50_NP results_NNS ,_, including_VBG standard_JJ deviations_NNS and_CC ranges_NNS ,_, are_VBP summarized_VBN in_IN Table_NP ._SENT The_DT average_JJ IC50s_NN for_IN the_DT isolates_NNS at_IN the_DT start_NN of_IN treatment_NN were_VBD 1.1_CD +-_NN 7.4_CD and_CC 0.28_CD +-_NN 0.28_CD mug_NN of_IN PCV/ml_NP for_IN the_DT PCV-_NN and_CC placebo-treated_JJ groups_NNS ,_, respectively_RB ._SENT As_RB discussed_VBN below_RB ,_, first_JJ virus_NN isolates_VBZ from_IN two_CD patients_NNS were_VBD resistant_JJ to_TO PCV_NP ;_: subsequent_JJ isolates_NNS from_IN these_DT patients_NNS were_VBD sensitive_JJ to_TO PCV_NP ._SENT Analysis_NN of_IN the_DT first-isolate_JJ data_NNS after_IN removal_NN of_IN the_DT IC50s_NP for_IN these_DT two_CD isolates_NNS (_( 55_CD and_CC 83_CD mug_NN of_IN PCV/ml_NP )_) resulted_VBD in_IN similar_JJ susceptibility_NN profiles_NNS overall_JJ for_IN the_DT two_CD treatment_NN groups_NNS (_( 0.29_CD +-_NN 0.25_CD and_CC 0.28_CD +-_NN 0.28_CD mug_NN of_IN PCV/ml_NP for_IN the_DT PCV-_NN and_CC placebo-treated_JJ groups_NNS ,_, respectively_RB )_) ._SENT Lastly_RB ,_, similar_JJ average_JJ IC50s_NNS were_VBD reported_VBN for_IN all_DT last_JJ isolates_NNS regardless_RB of_IN treatment_NN (_( 0.32_CD +-_NN 0.33_CD and_CC 0.31_CD +-_NN 0.33_CD mug_NN of_IN PCV/ml_NP for_IN the_DT PCV-_NN and_CC placebo-treated_JJ groups_NNS ,_, respectively_RB )_) ._SENT The_DT trend_NN analysis_NN on_IN data_NNS for_IN paired_VBN isolates_NNS (_( first_JJ and_CC last_JJ HSV_NP isolates_NNS tested_VBN for_IN PCV_NP susceptibility_NN )_) from_IN this_DT study_NN indicates_VBZ there_EX are_VBP no_RB statistically_RB significant_JJ differences_NNS between_IN IC50s_NP for_IN last_JJ isolates_NNS from_IN PCV-treated_JJ and_CC placebo-treated_JJ patient_JJ populations_NNS after_IN accounting_NN for_IN any_DT difference_NN in_IN the_DT IC50s_NP for_IN first_JJ viral_JJ isolates_NNS (_( P_NN =_SYM 0.791_CD by_IN analysis_NN of_IN covariance_NN )_) ._SENT Furthermore_RB ,_, monitoring_VBG changes_NNS in_IN IC50s_NP between_IN first_JJ and_CC last_JJ isolates_NNS can_MD serve_VB as_IN a_DT powerful_JJ method_NN to_TO identify_VB alterations_NNS in_IN the_DT pattern_NN of_IN susceptibility_NN during_IN therapy_NN ._SENT The_DT histogram_NN in_IN Fig._NN illustrates_VBZ the_DT differences_NNS in_IN IC50_NP (_( IC50_NP for_IN last_JJ isolate_NN minus_CC IC50_NN for_IN first_JJ isolate_NN )_) between_IN the_DT paired_VBN first_JJ and_CC last_JJ isolates_NNS for_IN each_DT treatment_NN group_NN ,_, up_RB to_TO an_DT increase_NN of_IN 2.5_CD mug_NN of_IN PCV/ml_NP ._SENT Only_RB two_CD isolates_NNS ,_, the_DT two_CD Pcvr_NP variants_NNS ,_, had_VBD IC50_JJ changes_NNS greater_JJR than_IN 2.5_CD mug_NN of_IN PCV/ml_NP ._SENT Several_JJ peaks_NNS ,_, representing_VBG subpopulations_NNS with_IN increasing_VBG IC50s_NP ,_, were_VBD apparent_JJ in_IN the_DT PCV_NP and_CC placebo_NN treatment_NN groups_NNS ._SENT Clearly_RB ,_, for_IN the_DT majority_NN of_IN samples_NNS evaluated_VBN ,_, similar_JJ profiles_NNS were_VBD apparent_JJ for_IN the_DT two_CD treatment_NN groups_NNS ._SENT However_RB ,_, to_TO the_DT right_NN of_IN the_DT midpoint_NN ,_, which_WDT corresponds_VBZ to_TO no_DT change_NN in_IN the_DT IC50_NN between_IN first_JJ and_CC last_JJ isolates_NNS ,_, three_CD minor_JJ peaks_NNS in_IN the_DT PCV-treated_JJ population_NN and_CC one_CD minor_JJ peak_NN in_IN the_DT placebo-treated_JJ group_NN were_VBD present_JJ ._SENT For_IN three_CD PCV-treated_JJ samples_NNS ,_, the_DT last_JJ PCV_NP IC50_NP was_VBD approximately_RB 0.65_CD to_TO 0.7_CD ,_, 0.75_CD to_TO 0.80_CD ,_, or_CC 1.0_CD to_TO 1.5_CD mug/ml_NN higher_JJR than_IN the_DT IC50_NN for_IN the_DT first_JJ isolate_NN (_( Fig._NN ,_, peaks_VBZ A_NP ,_, B_NP ,_, and_CC C_NP ,_, respectively_RB )_) ._SENT For_IN one_CD placebo-treated_JJ last_JJ isolate_NN ,_, the_DT PCV_NP IC50_NP was_VBD more_JJR than_IN 1.5_CD mug/ml_NN greater_JJR than_IN that_DT for_IN the_DT corresponding_JJ first_JJ isolate_NN (_( Fig._NN ,_, peak_NN D_NN )_) ._SENT Overall_RB ,_, however_RB ,_, for_IN the_DT majority_NN of_IN isolates_NNS ,_, the_DT distribution_NN profiles_NNS of_IN the_DT two_CD treatment_NN groups_NNS overlap_VBP ,_, suggesting_VBG that_IN no_DT significant_JJ differences_NNS in_IN susceptibility_NN are_VBP present_JJ between_IN treatment_NN groups_NNS ,_, although_IN the_DT minor_JJ increases_NNS in_IN IC50_NP for_IN four_CD patient_JJ samples_NNS tested_VBN could_MD indicate_VB a_DT trend_NN to_TO increasing_VBG resistance_NN or_CC simply_RB represent_VB the_DT inherent_JJ variability_NN within_IN the_DT plaque_NN reduction_NN assay_NN ._SENT PCV_NP susceptibilities_NNS of_IN all_DT HSV_NP isolates_VBZ ._SENT |_SYM Table_NP summarizes_VBZ the_DT susceptibility_NN data_NNS for_IN all_DT HSV_NP isolates_NNS (_( paired_VBN and_CC nonpaired_JJ )_) collected_VBN during_IN the_DT two_CD clinical_JJ trials_NNS ._SENT Once_RB again_RB ,_, average_JJ IC50s_NNS for_IN the_DT two_CD groups_NNS of_IN isolates_NNS were_VBD very_RB similar_JJ ,_, as_RB measured_VBN by_IN susceptibility_NN to_TO PCV_NP in_IN the_DT plaque_NN reduction_NN assay_NN (_( 0.29_CD +-_NN 0.28_CD and_CC 0.28_CD +-_NN 0.29_CD mug_NN of_IN PCV/ml_NP for_IN the_DT PCV-_NN and_CC placebo-treated_JJ groups_NNS ,_, respectively_RB )_) ,_, when_WRB IC50s_NP for_IN the_DT two_CD resistant_JJ first_JJ isolates_NNS were_VBD excluded_VBN ._SENT Inclusion_NN of_IN the_DT two_CD Pcvr_NP isolates_NNS in_IN the_DT data_NNS set_VBD results_NNS in_IN an_DT average_JJ IC50_NN of_IN 0.60_CD +-_NN 4.7_CD mug_NN of_IN PCV/ml_NP for_IN the_DT PCV-treated_JJ group_NN ._SENT Inclusion_NN of_IN these_DT highly_RB resistant_JJ isolates_NNS in_IN the_DT test_NN population_NN provides_VBZ the_DT most_RBS accurate_JJ representation_NN of_IN the_DT background_NN frequency_NN of_IN Pcvr_NP ,_, approximately_RB 0.34_CD %_NN (_( 2_CD of_IN 585_CD patients_NNS )_) ._SENT PCV-resistant_JJ clinical_JJ isolates_NNS ._SENT |_SYM PCV_NP IC50s_NP for_IN virus_NN isolates_NNS taken_VBN from_IN two_CD patients_NNS (_( patients_NNS 024.028.2586_CD and_CC 024.023.0495_CD )_) within_IN 17_CD h_NN of_IN the_DT start_NN of_IN PCV_NP treatment_NN were_VBD 83_CD and_CC 55_CD mug/ml_NN ,_, respectively_RB ,_, clearly_RB meeting_VBG the_DT criteria_NNS defining_VBG resistance_NN ._SENT However_RB ,_, subsequent_JJ isolates_NNS from_IN these_DT two_CD patients_NNS taken_VBN from_IN the_DT same_JJ episode_NN were_VBD susceptible_JJ to_TO PCV_NP (_( PCV_NP IC50s_NP ,_, 1.1_CD and_CC 0.8_CD mug/ml_NN ,_, respectively_RB ;_: viruses_NNS were_VBD isolated_VBN on_IN day_NN 3_CD of_IN treatment_NN in_IN both_DT cases_NNS )_) ._SENT No_DT other_JJ Pcvr_NP viruses_NNS were_VBD identified_VBN from_IN the_DT treatment_NN period_NN or_CC after_IN cessation_NN of_IN treatment_NN with_IN topical_JJ PCV_NP ._SENT Only_RB for_IN two_CD other_JJ isolates_NNS were_VBD PCV_NP IC50s_NP equal_JJ to_TO or_CC greater_JJR than_IN 2_CD mug/ml_NN ;_: both_CC of_IN these_DT were_VBD from_IN patients_NNS treated_VBN with_IN a_DT placebo_NN ._SENT For_IN one_CD isolate_NN ,_, obtained_VBN on_IN day_NN 3_CD from_IN patient_JJ 024.027.0424_CD ,_, the_DT IC50_NP was_VBD 3.1_CD mug/ml_NN ,_, but_CC this_DT value_NN was_VBD substantially_RB below_IN 9_CD mug/ml_NN ,_, the_DT breakpoint_NN defined_VBN as_IN 10-fold_NN above_IN the_DT IC50_NN for_IN the_DT wild_JJ type_NN ._SENT When_WRB the_DT isolate_NN was_VBD retested_VBN against_IN PCV_NP ,_, an_DT IC50_NP of_IN 0.74_CD mug/ml_NN was_VBD determined_VBN ,_, and_CC therefore_RB this_DT isolate_NN was_VBD not_RB considered_VBN to_TO be_VB resistant_JJ to_TO PCV_NP ._SENT For_IN another_DT isolate_NN (_( obtained_VBN on_IN day_NN 1_CD from_IN patient_NN 024.028.2016_CD )_) ,_, the_DT IC50_NP was_VBD 2_CD mug/ml_NN ._SENT The_DT IC50_NP for_IN the_DT sensitive_JJ control_NN strain_NN ranged_VBD between_IN 0.9_CD and_CC 1.6_CD mug/ml_NN ,_, and_CC therefore_RB ,_, according_VBG to_TO the_DT 10-fold_NN criterion_NN ,_, the_DT test_NN isolate_NN was_VBD classified_VBN as_IN sensitive_JJ ;_: however_RB ,_, based_VBN on_IN the_DT standard_JJ breakpoint_NN of_IN an_DT IC50_NN of_IN >=2.0_JJ mug/ml_NN ,_, this_DT isolate_NN would_MD be_VB labeled_VBN as_IN possibly_RB resistant_JJ ._SENT Unfortunately_RB ,_, this_DT isolate_NN was_VBD not_RB available_JJ for_IN further_JJR analysis_NN or_CC retesting_NN ._SENT Molecular_JJ characterization_NN of_IN Pcvr_NP isolates_VBZ ._SENT |_SYM Plaque_NP autoradiography_NN on_IN the_DT two_CD Pcvr_NP patient_JJ samples_NNS (_( patients_NNS 024.028.2586_CD and_CC 024.023.0495_CD )_) confirmed_VBD that_IN the_DT resistant_JJ variants_NNS represented_VBD the_DT majority_NN of_IN virus_NN present_NN in_IN the_DT virus_NN preparation_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Plaque-purified_JJ isolates_NNS from_IN the_DT two_CD patient_JJ samples_NNS which_WDT were_VBD confirmed_VBN as_IN Pcvr_NP (_( patients_NN 024.028.2586_CD and_CC 024.023.0495_CD )_) were_VBD evaluated_VBN for_IN the_DT ability_NN to_TO phosphorylate_VB 3H-labeled_JJ substrates_NNS including_VBG thymidine_NN ,_, ACV_NP ,_, and_CC PCV_NP according_VBG to_TO previously_RB described_VBN methods_NNS ._SENT These_DT isolates_NNS were_VBD unable_JJ to_TO utilize_VB ACV_NP or_CC PCV_NP as_IN a_DT substrate_NN ,_, compared_VBN to_TO phosphorylation_NN by_IN wild-type_NP HSV-1_NP (_( set_VBN at_IN 100_CD %_NN )_) ,_, and_CC they_PP were_VBD also_RB highly_RB impaired_VBN in_IN thymidine_NN phosphorylation_NN ,_, suggestive_JJ of_IN a_DT TK-negative_JJ or_CC TK-partial_JJ phenotype_NN ._SENT Lastly_RB ,_, PCV_NP IC50s_NP were_VBD reduced_VBN to_TO below_RB 0.7_CD mug/ml_NN upon_IN testing_NN in_IN BUHK-TK_NP cells_NNS (_( data_NNS not_RB shown_VBN )_) ,_, confirming_VBG that_IN impaired_JJ TK_NP activity_NN was_VBD responsible_JJ for_IN conferring_VBG resistance_NN to_TO PCV_NP ._SENT However_RB ,_, the_DT important_JJ distinction_NN between_IN TK-negative_NP and_CC TK-partial_NP remains_VBZ difficult_JJ to_TO make_VB based_VBN on_IN in_IN vitro_NP TK_NP assays_VBZ alone_RB ._SENT Sequence_NN analysis_NN of_IN the_DT TK_NP coding_VBG region_NN identified_VBD the_DT presence_NN of_IN frameshift_NN mutations_NNS ,_, consistent_JJ with_IN the_DT TK-negative_JJ phenotype_NN ._SENT The_DT isolate_NN from_IN patient_JJ 024.028.2586_CD contained_VBD two_CD mutations_NNS ,_, a_DT deletion_NN of_IN residue_NN 65_CD (_( threonine_NN )_) and_CC a_DT frameshift_NN (_( cytosine_NN insertion_NN )_) in_IN the_DT homopolymeric_JJ C_NP run_NN at_IN residue_NN 185_CD ._SENT The_DT isolate_NN obtained_VBN from_IN patient_JJ 024.023.0495_CD contained_VBD three_CD nonconservative_JJ changes_NNS and_CC a_DT frameshift_NN at_IN residue_NN 270_CD (_( cytosine_NN deletion_NN )_) ._SENT It_PP was_VBD not_RB determined_VBN whether_IN the_DT nonconservative_JJ residues_NNS and/or_CC frameshift_NN was_VBD directly_RB responsible_JJ for_IN conferring_VBG drug_NN resistance_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Changes_NP in_IN IC50_NP between_IN first_JJ and_CC last_JJ HSV-1_JJ isolates_NNS ._SENT Changes_NNS in_IN IC50_NP between_IN first_JJ and_CC last_JJ HSV-1_JJ isolates_NNS ._SENT This_DT parameter_NN was_VBD utilized_VBN to_TO identify_VB alterations_NNS or_CC trends_NNS in_IN the_DT pattern_NN of_IN susceptibility_NN during_IN the_DT course_NN of_IN therapy_NN ._SENT Differences_NNS between_IN the_DT IC50_NN for_IN the_DT last_JJ isolate_NN and_CC that_IN for_IN the_DT first_JJ isolate_NN are_VBP shown_VBN as_IN ranges_NNS (_( in_IN micrograms_NNS of_IN PCV_NP per_IN milliliter_NN )_) on_IN the_DT y_NP axis_NN ._SENT Numbers_NNS of_IN patients_NNS analyzed_VBN are_VBP shown_VBN on_IN the_DT x_NN axis_NN ._SENT The_DT distributions_NNS of_IN susceptibility_NN are_VBP similar_JJ for_IN the_DT two_CD treatment_NN groups_NNS except_IN for_IN four_CD minor_JJ populations_NNS ._SENT Peaks_NP A_NP through_IN C_NP represent_VBP three_CD minor_JJ populations_NNS in_IN the_DT PCV-treated_JJ group_NN with_IN a_DT shift_NN to_TO the_DT right_NN in_IN susceptibility_NN ,_, and_CC peak_NN D_NN corresponds_VBZ to_TO one_CD minor_JJ population_NN in_IN the_DT placebo-treated_JJ group_NN with_IN decreased_VBN susceptibility_NN to_TO PCV_NP ._SENT FIG._NN 2_CD ._SENT |_SYM Alignment_NN of_IN mutations_NNS within_IN the_DT TK_NP coding_VBG sequence_NN ._SENT Alignment_NN of_IN mutations_NNS within_IN the_DT TK_NP coding_VBG sequence_NN ._SENT The_DT schematic_JJ representation_NN depicts_VBZ the_DT HSV-1_NP TK_NP polypeptide_NN and_CC three_CD conserved_VBN domains_NNS ,_, the_DT nucleotide_NN binding_VBG pocket_NN ,_, the_DT thymidine_NN binding_VBG site_NN ,_, and_CC the_DT ATP_NP binding_JJ site_NN ._SENT The_DT homopolymeric_JJ hot-spot_NN regions_NNS (_( G7_JJ and_CC C6_JJ )_) are_VBP indicated_VBN ._SENT Below_IN the_DT diagram_NN ,_, the_DT genotypic_JJ mutations_NNS and_CC resulting_VBG residue_NN changes_NNS or_CC frameshifts_NNS (_( FS_NN )_) identified_VBN in_IN the_DT two_CD confirmed_VBD Pcvr_NP isolates_NNS are_VBP shown_VBN ._SENT TABLE_NN 1_CD |_SYM Analysis_NN of_IN PCV_NP susceptibilities_NNS of_IN paired_VBN HSV-1_JJ isolates_NNS TABLE_NP 2_CD |_SYM Analysis_NN of_IN PCV_NP susceptibilities_NNS of_IN all_DT HSV-1_JJ isolates_NNS ,_, paired_VBN and_CC nonpaired_VBN TABLE_NP 3_CD |_SYM Biochemical_NP characterization_NN of_IN Pcvr_NP HSV-1_NP isolates_VBZ This_DT study_NN demonstrates_VBZ that_IN there_EX is_VBZ no_DT evidence_NN of_IN reduced_VBN PCV_NP sensitivity_NN among_IN viral_JJ isolates_NNS obtained_VBN from_IN patients_NNS treating_VBG a_DT single_JJ episode_NN of_IN recurrent_JJ herpes_NN labialis_NNS with_IN topical_JJ PCV_NP ._SENT No_DT statistically_RB significant_JJ difference_NN between_IN the_DT PCV_NP and_CC placebo_NN treatment_NN groups_NNS was_VBD identified_VBN in_IN the_DT IC50s_NP for_IN first_JJ isolates_NNS (_( P_NN =_SYM 0.796_CD )_) or_CC the_DT IC50s_NP for_IN last_JJ isolates_NNS (_( P_NN =_SYM 0.757_CD )_) ._SENT Furthermore_RB ,_, the_DT average_JJ difference_NN between_IN IC50s_NP for_IN paired_VBN isolates_NNS in_IN the_DT PCV_NP group_NN was_VBD 0.028_CD ,_, and_CC that_IN in_IN the_DT placebo_NN group_NN was_VBD 0.025_CD ._SENT Thus_RB ,_, there_EX was_VBD no_DT statistically_RB significant_JJ difference_NN between_IN the_DT last_JJ and_CC first_JJ IC50s_NNS in_IN either_CC the_DT PCV-treated_JJ group_NN (_( P_NN =_SYM 0.078_CD )_) or_CC the_DT placebo-treated_JJ group_NN (_( P_NN =_SYM 0.065_CD )_) ._SENT The_DT plaque_NN reduction_NN assay_NN data_NNS ,_, along_RB with_IN the_DT histogram_NN analysis_NN presented_VBN in_IN Fig._NN ,_, confirm_VBP that_IN acute_JJ treatment_NN of_IN recurrent_JJ herpes_NN labialis_NNS in_IN immunocompetent_JJ patients_NNS with_IN topical_JJ PCV_NP did_VBD not_RB result_VB in_IN an_DT increase_NN in_IN the_DT prevalence_NN of_IN resistant_JJ HSV_NP ._SENT Collecting_VBG serial_JJ isolates_NNS represents_VBZ a_DT powerful_JJ method_NN for_IN examining_VBG trends_NNS in_IN resistance_NN ._SENT Since_IN the_DT distribution_NN profiles_NNS of_IN changes_NNS in_IN IC50_NP after_IN treatment_NN significantly_RB overlap_VBP for_IN the_DT two_CD treatment_NN groups_NNS ,_, acute_JJ treatment_NN with_IN PCV_NP cream_NN versus_IN a_DT placebo_NN does_VBZ not_RB appear_VB to_TO increase_VB the_DT likelihood_NN of_IN selecting_VBG for_IN Pcvr_NP HSV_NP in_IN immunocompetent_JJ patients_NNS with_IN recurrent_JJ herpes_NN labialis_NNS ._SENT However_RB ,_, studies_NNS monitoring_VBG resistance_NN trends_NNS during_IN episodic_JJ ,_, prolonged_JJ treatment_NN need_VBP to_TO be_VB performed_VBN in_IN order_NN to_TO assess_VB the_DT development_NN of_IN resistance_NN over_IN time_NN with_IN repeated_JJ usage_NN ._SENT Two_CD virus_NN isolates_NNS for_IN which_WDT PCV_NP IC50s_NP were_VBD 55_CD and_CC 83_CD mug/ml_NN were_VBD confirmed_VBN by_IN biochemical_JJ and_CC molecular_JJ analyses_NNS to_TO be_VB Pcvr_NP ._SENT Both_DT were_VBD first_JJ isolates_NNS ,_, taken_VBN within_IN 17_CD h_NN of_IN the_DT start_NN of_IN treatment_NN with_IN topical_JJ PCV_NP ._SENT Spontaneous_JJ mutations_NNS within_IN the_DT HSV_NP genome_NN are_VBP introduced_VBN by_IN errors_NNS during_IN DNA_NN replication_NN and_CC are_VBP independent_JJ of_IN the_DT presence_NN of_IN an_DT antiviral_JJ agent_NN ._SENT This_DT natural_JJ phenomenon_NN results_NNS in_IN the_DT accumulation_NN of_IN 6_CD to_TO 8_CD TK-deficient_JJ variants_NNS per_IN 104_CD plaque-forming_JJ viruses_NNS in_IN virus_NN populations_NNS that_WDT have_VBP never_RB been_VBN exposed_VBN to_TO selective_JJ pressure_NN and_CC can_MD explain_VB the_DT coexistence_NN of_IN both_DT resistant_JJ and_CC sensitive_JJ viruses_NNS within_IN all_DT clinical_JJ HSV_NP isolates_NNS ._SENT Consistent_JJ with_IN this_DT ,_, there_EX is_VBZ a_DT low_JJ prevalence_NN of_IN resistant_JJ HSV_NP among_IN individuals_NNS who_WP have_VBP not_RB been_VBN treated_VBN with_IN an_DT antiviral_JJ agent_NN ._SENT Given_VBN the_DT replication_NN cycle_NN kinetics_NNS of_IN HSV_NP and_CC the_DT fact_NN that_IN both_DT Pcvr_NP isolates_NNS were_VBD obtained_VBN within_IN 17_CD h_NN of_IN initiation_NN of_IN treatment_NN ,_, it_PP seems_VBZ unlikely_JJ ,_, although_IN possible_JJ ,_, that_IN they_PP resulted_VBD from_IN selection_NN pressure_NN as_IN the_DT result_NN of_IN antiviral_JJ treatment_NN ._SENT Since_IN approximately_RB 50_CD %_NN resistant_JJ variants_NNS are_VBP required_VBN within_IN a_DT virus_NN preparation_NN to_TO confer_VB such_JJ high_JJ IC50s_NP ,_, a_DT preexisting_VBG resistant_JJ variant_NN would_MD have_VB to_TO represent_VB a_DT substantial_JJ proportion_NN of_IN the_DT virus_NN swab_NN and_CC be_VB selectively_RB amplified_VBN immediately_RB upon_IN the_DT initiation_NN of_IN treatment_NN ._SENT Although_IN the_DT presence_NN of_IN these_DT two_CD resistant_JJ isolates_NNS from_IN the_DT first_JJ isolate_NN swabs_NNS may_MD simply_RB reflect_VB the_DT natural_JJ heterogeneity_NN of_IN HSV_NP populations_NNS ,_, isolates_NNS taken_VBN on_IN day_NN 2_CD would_MD be_VB expected_VBN to_TO also_RB be_VB resistant_JJ ,_, yet_RB these_DT IC50s_NP were_VBD below_RB 2.0_CD mug/ml_NN ._SENT Another_DT possible_JJ explanation_NN is_VBZ that_IN these_DT two_CD isolates_VBZ result_NN from_IN rare_JJ cases_NNS where_WRB residual_JJ topical_JJ PCV_NP carried_VBD from_IN the_DT viral_JJ swab_NN facilitated_VBN in_IN vitro_NN selection_NN of_IN resistant_JJ virus_NN during_IN the_DT isolation_NN process_NN ._SENT If_IN this_DT is_VBZ true_JJ ,_, isolates_NNS obtained_VBD from_IN these_DT patients_NNS on_IN days_NNS 2_CD and_CC 3_CD would_MD be_VB expected_VBN to_TO be_VB completely_RB susceptible_JJ to_TO PCV_NP ._SENT A_DT third_JJ explanation_NN which_WDT cannot_MD be_VB ruled_VBN out_RP is_VBZ preferential_JJ selection_NN for_IN resistant_JJ variants_NNS on_IN day_NN 1_CD ,_, followed_VBN by_IN subsequent_JJ selection_NN against_IN these_DT isolates_NNS for_IN fitness_NN ._SENT Lastly_RB ,_, patient_JJ recording_NN of_IN treatment_NN times_NNS indicates_VBZ that_DT lack_NN of_IN compliance_NN was_VBD not_RB a_DT factor_NN in_IN the_DT selection_NN for_IN resistance_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Genotypic_JJ characterization_NN of_IN the_DT two_CD confirmed_VBD Pcvr_NP HSV_NP isolates_NNS described_VBD in_IN this_DT report_NN resulted_VBD in_IN the_DT identification_NN of_IN a_DT frameshift_NN mutation_NN at_IN residue_NN 185_CD in_IN one_CD isolate_NN ,_, which_WDT was_VBD also_RB found_VBN in_IN a_DT previously_RB characterized_VBN Pcvr_NP isolate_NN and_CC is_VBZ similar_JJ to_TO the_DT mutations_NNS routinely_RB found_VBD within_IN the_DT homopolymeric_JJ region_NN of_IN TK_NP (_( G7_NP and_CC C6_NP hot_JJ spots_NNS )_) ._SENT Moreover_RB ,_, several_JJ mutations_NNS were_VBD also_RB identified_VBN in_IN the_DT second_JJ isolate_NN characterized_VBD ,_, notably_RB with_IN a_DT frameshift_NN at_IN residue_NN 270_CD ,_, which_WDT ,_, like_IN the_DT frameshift_NN at_IN residue_NN 185_CD ,_, could_MD be_VB predicted_VBN to_TO disrupt_VB the_DT integrity_NN of_IN the_DT ATP/nucleoside_NP binding_JJ pocket_NN ._SENT Interestingly_RB ,_, although_IN these_DT isolates_NNS were_VBD plaque_NN purified_VBN several_JJ times_NNS ,_, they_PP were_VBD not_RB absolutely_RB defective_JJ in_IN the_DT ability_NN to_TO phosphorylate_JJ thymidine_NN ,_, whereas_IN phosphorylation_NN of_IN ACV_NP and_CC PCV_NP was_VBD below_IN the_DT level_NN of_IN detection_NN ._SENT It_PP is_VBZ not_RB known_VBN whether_IN the_DT minor_JJ level_NN of_IN thymidine_NN phosphorylation_NN is_VBZ due_JJ to_TO contamination_NN with_IN wild-type_NN virus_NN undetectable_JJ by_IN plaque_NN autoradiography_NN ,_, to_TO ribosomal_JJ frameshifting_NN ,_, or_CC to_TO other_JJ factors_NNS ._SENT Most_RBS recently_RB ,_, the_DT prevalence_NN of_IN ACV_NP resistance_NN was_VBD determined_VBN to_TO be_VB approximately_RB 0.4_CD %_NN based_VBN on_IN data_NNS for_IN HSV_NP isolates_NNS obtained_VBN from_IN 708_CD immunocompetent_NN ,_, ACV-naive_JJ individuals_NNS with_IN genital_JJ herpes_NN ._SENT Furthermore_RB ,_, the_DT proportion_NN of_IN ACV_NP resistance_NN appears_VBZ to_TO be_VB relatively_RB stable_JJ in_IN immunocompetent_JJ patients_NNS ,_, even_RB after_IN the_DT increased_VBN usage_NN of_IN ACV_NP over_IN the_DT past_JJ 2_CD decades_NNS ._SENT The_DT present_JJ study_NN indicates_VBZ that_IN the_DT overall_JJ prevalence_NN of_IN PCV-resistant_NP HSV_NP isolates_VBZ ,_, for_IN the_DT immunocompetent_JJ population_NN examined_VBD ,_, was_VBD no_RB greater_JJR than_IN 0.19_CD %_NN ,_, in_IN agreement_NN with_IN historical_JJ data_NNS on_IN ACV_NP ._SENT Although_IN PCV_NP and_CC ACV_NP share_NN an_DT identical_JJ activation_NN pathway_NN and_CC a_DT similar_JJ mode_NN of_IN action_NN ,_, suggesting_VBG that_IN the_DT mechanisms_NNS of_IN resistance_NN are_VBP similar_JJ ,_, the_DT widespread_JJ usage_NN of_IN ACV_NP for_IN treatment_NN has_VBZ not_RB increased_VBN the_DT prevalence_NN of_IN PCV_NP resistance_NN above_IN that_WDT reported_VBD for_IN ACV_NP ._SENT In_IN conclusion_NN ,_, based_VBN on_IN the_DT PCV_NP susceptibilities_NNS of_IN sequential_JJ isolates_NNS from_IN patients_NNS with_IN recurrent_JJ herpes_NN labialis_NNS taken_VBN throughout_IN the_DT treatment_NN period_NN in_IN this_DT study_NN ,_, there_EX is_VBZ no_DT reason_NN to_TO expect_VB a_DT change_NN in_IN the_DT overall_JJ prevalence_NN of_IN resistant_JJ HSV_NP isolates_NNS with_IN use_NN of_IN topical_JJ PCV_NP for_IN acute_JJ treatment_NN of_IN recurrent_JJ herpes_NN labialis_NNS in_IN immunocompetent_JJ patients_NNS ._SENT 